Compare CWT & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWT | IMNM |
|---|---|---|
| Founded | 1926 | 2006 |
| Country | United States | United States |
| Employees | 1105 | N/A |
| Industry | Water Supply | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 1997 | 2020 |
| Metric | CWT | IMNM |
|---|---|---|
| Price | $45.12 | $22.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $54.50 | $32.10 |
| AVG Volume (30 Days) | 318.5K | ★ 987.9K |
| Earning Date | 06-03-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | N/A | ★ 7.06 |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $963,695,000.00 | $9,041,000.00 |
| Revenue This Year | $9.48 | N/A |
| Revenue Next Year | $3.84 | $11.53 |
| P/E Ratio | $20.93 | ★ N/A |
| Revenue Growth | ★ 6.41 | N/A |
| 52 Week Low | $41.29 | $5.15 |
| 52 Week High | $51.23 | $27.65 |
| Indicator | CWT | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 46.03 |
| Support Level | $44.20 | $18.98 |
| Resistance Level | $46.98 | $22.57 |
| Average True Range (ATR) | 0.96 | 1.20 |
| MACD | -0.10 | -0.22 |
| Stochastic Oscillator | 40.87 | 24.19 |
California Water Service Group is a U.S. water and utilities holding company based in California. The company engages in the production, treatment, storage, distribution, and sale of water for various uses. The firm operates through its subsidiaries, which can be divided between regulated and unregulated businesses. The regulated public utilities subsidiaries operate in California, New Mexico, Washington, and Hawaii. The unregulated subsidiaries provide water utility services to private companies and municipalities. The company derives the majority of its revenue from its operations in California and, overall, from residential customers.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.